New treatment options for nonsurgical management of uterine fibroids
- PMID: 37144584
- PMCID: PMC10330353
- DOI: 10.1097/GCO.0000000000000880
New treatment options for nonsurgical management of uterine fibroids
Abstract
Purpose of review: Uterine fibroids is a common problem in reproductive-age individuals, frequently causing abnormal uterine bleeding, bulk symptoms, and adverse reproductive outcomes. Traditionally, almost half of the women with symptomatic fibroids received surgery for definitive treatment. There are a growing number of nonsurgical options for treatment that have become available for patients who desire conservative treatment or those with contraindications to surgery.
Recent findings: The introduction of oral gonadotropin-releasing hormone antagonists in combination with low-dose physiologic hormonal therapy demonstrated improvement in heavy menstrual bleeding, pain, and quality of life with preservation of bone density and a modest reduction in uterine volume with few hypogonadal side effects. Magnetic resonance-guided focused ultrasound surgery and uterine artery embolization continue to be minimally invasive procedural alternatives to hysterectomy that are safe and effective.
Summary: As more options for conservative management of uterine fibroids became available, it is important to counsel patients on possible options based on the size, location, and number of the fibroids as well as severity of the symptoms, plans for pregnancy, how close they are to menopause and their treatment goals.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest: Dr. Stewart reports that within the last three years money was paid to her institution from AHRQ/PCORI for grant P50 HS023418 regarding uterine fibroids and from Eunice Kennedy Shiver Institute of Child Health and Human Development, National Institutes of Health, for grant R01HD105714 regarding adenomyosis. She has served as a consultant for and received payment from AbbVie, ObsEva, and Myovant related to uterine fibroids and oral GnRH antagonists. She holds a patent for Methods and Compounds for Treatment of Abnormal Uterine Bleeding (US 6440445), which has no commercial activity. She has received royalties from UpToDate and payments for the development of educational content from the Med Learning Group, MED-IQ, Medscape, PER, Omnia Education, and WebMD. She also serves as an unpaid advisor to the Fibroid Foundation. Dr. Lee reports no conflicts on interest.
References
-
-
**American College Obstetricans and Gynecologists. Management of symptomatic uterine leiomyomas: ACOG practice bulletin, number 228. Obstet Gynecol 2021; 137:e100–e115.
Comprehensive evidence--based review regarding clinical management of symptomatic uteine leiomyomas.
-
-
-
*Stewart EA, Nowak RA. Uterine fibroids: hiding in plain sight. Physiology 2022; 37:16–27.
Updated review of pathophysiology and biology of uterine fibroids.
-
-
-
*Liao L, Chen L, Melamed A et al. Use of Conservative Therapies Before Hysterectomy for Uterine Leiomyomas. Obstet Gynecol 2023;141:371–374
In patients who underwent hysterectomy for uterine fibroids, 59.7% did not receive any conservative treatment before the surgery.
-
-
- Corona LE, Swenson CW, Sheetz KH et al. Use of other treatments before hysterectomy for benign conditions in a statewide hospital collaborative. Am J Obstet Gynecol 2015; 212:304. e1–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
